Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target raised by analysts at Truist Financial Co. from $25.00 to $33.00. They now have a "buy" rating on the stock.
Edgewise Therapeutics, Inc. (EWTX)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
EWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EWTX alerts
High impacting Edgewise Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
EWTX
News
- Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target raised by analysts at Wedbush from $44.00 to $45.00. They now have an "outperform" rating on the stock.MarketBeat
- Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsBusiness Wire
- Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target raised by analysts at Piper Sandler from $48.00 to $51.00. They now have an "overweight" rating on the stock.MarketBeat
- Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle SocietyBusiness Wire
- Edgewise's EDG-7500 shows benefit in two obstructive HCM trials [Yahoo! Finance]Yahoo! Finance
EWTX
Earnings
- 8/8/24 - Beat
EWTX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- EWTX's page on the SEC website